Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic/Myeloproliferative Neoplasms: early-phase trial registry
3 of 16 indexed Myelodysplastic/Myeloproliferative Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 3 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Myelodysplastic/Myeloproliferative Neoplasms: 16 US clinical trials tracked, 3 recruiting.
Myelodysplastic/Myeloproliferative Neoplasms is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 2 of these trials.
Enrollment posture brief
Registry condition myelodysplasticmyeloproliferative-neoplasms
OPEN 3 | RECR 19% | LATE 3 | EARLY 8 | RANK #1060 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Bacterial Vaginosis (19% recruiting · 16 trials)
Myelodysplastic/Myeloproliferative Neoplasms lists 3 open slots (19% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelodysplastic/Myeloproliferative Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelodysplastic/Myeloproliferative Neoplasms is recruiting below its size-band peers.
3 of 16 indexed trials (18.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Myelodysplastic/Myeloproliferative Neoplasms trials is spread across many organizations.
Children's Oncology Group accounts for 2 of 16 trials (12.5%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Myelodysplastic/Myeloproliferative Neoplasms enrolment sits around 254 participants.
Median target enrolment is 254 among the 10 trials that report a genuine target (sentinel values excluded). 4 of those (40%) plan for fewer than 100 participants.
-
Myelodysplastic/Myeloproliferative Neoplasms research is mostly interventional.
12 interventional and 4 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01137643
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01137825
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
NCT00935090
S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer
SWOG Cancer Research Network
NCT00919425
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant
City of Hope Medical Center
NCT00964821
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
Children's Oncology Group
NCT00003593
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
Tufts Medical Center
NCT00782145
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
Vanderbilt-Ingram Cancer Center
NCT00666211
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Children's Oncology Group
NCT01164163
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
NCT00589563
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Ohio State University Comprehensive Cancer Center
NCT00624936
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
Memorial Sloan Kettering Cancer Center
NCT00014469
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
NCT00019656
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
NCT00064311
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
Fallon Clinic
NCT00053001
Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia
Memorial Sloan Kettering Cancer Center
NCT00006040
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelodysplastic/Myeloproliferative Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelodysplastic/Myeloproliferative Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelodysplastic/Myeloproliferative Neoplasms page
16 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Myelodysplastic/Myeloproliferative Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Children's Oncology Group sponsors the most Myelodysplastic/Myeloproliferative Neoplasms trials on record, review their full trial history before evaluating a specific study. See Children's Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelodysplastic/Myeloproliferative Neoplasms condition card totals 16 registered trials; most-linked intervention methotrexate; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.